A051901: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma (clinicaltrials.gov) - Oct 22, 2026 - P1 | N=47 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Apr 2027 ➔ Aug 2027 | Trial primary completion date: Apr 2027 ➔ Aug 2027
Trial completion date • Trial primary completion date • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Central Nervous System Lymphoma
|